Abstract
Investigation of mucociliary clearance (MCC) condition in 90 patients with COPD was performed according to the stage of the disease by determining the level of biochemical indicator of sputum - medium weight molecules (MWM). To determine the effect of chronic inflammation in the respiratory tract on a general condition of the organism, MWM content in blood serum was investigated. To reduce the influence of comorbidity on MWM content in blood serum, patients with COPD without or with mild comorbidity in remission were selected, and the results were compared with those of healthy people (control group, n = 20). The results showed a direct correlation between the severity of airflow limitation and concentration of MWM in sputum, this was accompanied by increasing of viscosity and adhesive performance of sputum and violation of the optimal conditions of MCC functioning. The fact established allows to use determination of MWM content in sputum of COPD patients as a noninvasive and accessible for pulmonology practice method, which allows to quickly and adequately assess MCC condition and aggregate of metabolic abnormalities in patients’ respiratory tract. Chronic inflammation in respiratory tract is accompanied by disorders of determined indicators in the serum as well, but increase of MWM content in sputum is specific, while the accumulation of MWM in serum of patients with COPD is not specific.
Highlights
Ɏɪɨɧɿɱɧɟ ɨɛɫɬɪɭɤɬɢɜɧɟ ɡɚɯɜɨɪɸɜɚɧɧɹ ɥɟɝɟɧɶ ɽ ɨɞɧɿɽɸ ɡ ɩɪɨɜɿɞɧɢɯ ɩɪɢɱɢɧ ɫɦɟɪɬɧɨɫɬɿ ɬɚ ɨɛɦɟɠɟɧɧɹ ɩɪɚɰɟɡɞɚɬɧɨɫɬɿ ɧɚɫɟɥɟɧɧɹ ɪɨɡɜɢɧɭɬɢɯ ɤɪɚʀɧ ɿɡ ɲɜɢɞɤɢɦ ɪɨɡɩɨɜɫɸɞɠɟɧɧɹɦ ɭ ɧɚɣɛɥɢɠɱɨɦɭ ɦɚɣɛɭɬɧɶɨɦɭ ɭ ɤɪɚʀɧɚɯ, ɳɨ ɪɨɡɜɢɜɚɸɬɶɫɹ [9]
Ɋɥɿɞ ɜɿɞɦɿɬɢɬɢ, ɳɨ ɜɚɪɿɚɛɟɥɶɧɿɫɬɶ ɤɨɧɰɟɧ- ɤɨɥɢɜɚɧɧɹ ɩɨɤɚɡɧɢɤɚ ɫɩɨɫɬɟɪɿɝɚɸɬɶɫɹ ɜ ɝɪɭɩɿ ɬɪɚɰɿɣ ɆɋɆ ɜ ɦɨɤɪɨɬɢɧɧɿ ɩɪɹɦɨ ɡɚɥɟɠɢɬɶ ɜɿɞ ɯɜɨɪɢɯ ɧɚ ɏɈɁɅ III ɫɬɚɞɿʀ, ɧɚɣɦɟɧɲɿ – ɩɪɢ ɏɈɁɅ ɫɬɭɩɟɧɹ ɛɪɨɧɯɿɚɥɶɧɨʀ ɨɛɫɬɪɭɤɰɿʀ – ɧɚɣɛɿɥɶɲɿ
F. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options / D.F. Rogers // Pulmonary Pharmacology Therapeutics
Summary
Ɏɪɨɧɿɱɧɟ ɨɛɫɬɪɭɤɬɢɜɧɟ ɡɚɯɜɨɪɸɜɚɧɧɹ ɥɟɝɟɧɶ (ɏɈɁɅ) ɽ ɨɞɧɿɽɸ ɡ ɩɪɨɜɿɞɧɢɯ ɩɪɢɱɢɧ ɫɦɟɪɬɧɨɫɬɿ ɬɚ ɨɛɦɟɠɟɧɧɹ ɩɪɚɰɟɡɞɚɬɧɨɫɬɿ ɧɚɫɟɥɟɧɧɹ ɪɨɡɜɢɧɭɬɢɯ ɤɪɚʀɧ ɿɡ ɲɜɢɞɤɢɦ ɪɨɡɩɨɜɫɸɞɠɟɧɧɹɦ ɭ ɧɚɣɛɥɢɠɱɨɦɭ ɦɚɣɛɭɬɧɶɨɦɭ ɭ ɤɪɚʀɧɚɯ, ɳɨ ɪɨɡɜɢɜɚɸɬɶɫɹ [9]. Ⱦɨɫɥɿɞɠɟɧɧɹ ɫɬɚɧɭ ɆɐɄ ɡɞɿɣɫɧɸɜɚɥɢ ɡɚɥɟɠɧɨ ɜɿɞ ɫɬɚɞɿʀ ɡɚɯɜɨɪɸɜɚɧɧɹ ɲɥɹɯɨɦ ɨɰɿɧɤɢ ɛɿɨɯɿɦɿɱɧɨɝɨ ɩɨɤɚɡɧɢɤɚ ɦɨɤɪɨɬɢɧɧɹ – ɦɨɥɟɤɭɥ ɫɟɪɟɞɧɶɨʀ ɦɚɫɢ (ɆɋɆ) [1]. 42,1±1,4 ɪȱȱ-ȱȱȱ < 0,001 ɋɬɚɧ ɆɐɄ ɜɢɜɱɚɥɢ ɭ ɯɜɨɪɢɯ ɧɚ ɏɈɁɅ ɭ ɤɥɿɧɿɱɧɨ ɫɬɚɛɿɥɶɧɨɦɭ ɫɬɚɧɿ ɡɚɥɟɠɧɨ ɜɿɞ ɫɬɭɩɟɧɹ ɜɢɪɚɡɧɨɫɬɿ ɛɪɨɧɯɿɚɥɶɧɨʀ ɨɛɫɬɪɭɤɰɿʀ ɡɚ ɪɿɜɧɟɦ ɆɋɆ ɦɨɤɪɨɬɢɧɧɹ. Ɍɨɛɬɨ ɩɪɨɝɪɟɫɭɜɚɧɧɹ ɛɪɨɧɯɿɚɥɶɧɨʀ ɨɛɫɬɪɭɤɰɿʀ ɫɭɩɪɨɜɨɞɠɭɽɬɶɫɹ ɬɟɧɞɟɧɰɿɽɸ ɞɨ ɩɿɞɜɢɳɟɧɧɹ ɜɦɿɫɬɭ ɆɋɆ (ɭ ɫɟɪɟɞɧɶɨɦɭ ɧɚ 10,0%) ɭ ɦɨɤɪɨɬɢɧɧɿ ɯɜɨɪɢɯ ɧɚ ɏɈɁɅ II ɫɬɚɞɿʀ (ɪ = 0,11).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
